OnKure Therapeutics, Inc.
OKUR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $44 | $32 | $26 | $28 |
| G&A Expenses | $11 | $5 | $4 | $0 |
| SG&A Expenses | $11 | $5 | $4 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $54 | $37 | $30 | $40 |
| Operating Income | -$54 | -$37 | -$30 | -$40 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $2 | $0 | $0 |
| Pre-Tax Income | -$53 | -$35 | -$30 | -$40 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$53 | -$35 | -$30 | -$40 |
| % Margin | – | – | – | – |
| EPS | -3.95 | -2.65 | -2.21 | -21.92 |
| % Growth | -49.1% | -19.9% | 89.9% | – |
| EPS Diluted | -3.95 | -2.65 | -2.21 | -21.92 |
| Weighted Avg Shares Out | 13 | 13 | 13 | 2 |
| Weighted Avg Shares Out Dil | 13 | 13 | 13 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $0 | $0 |
| EBITDA | -$52 | -$35 | -$29 | -$40 |
| % Margin | – | – | – | – |